Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.
2.

Adherence and persistence to urate-lowering therapies in the Irish setting.

McGowan B, Bennett K, Silke C, Whelan B.

Clin Rheumatol. 2016 Mar;35(3):715-21. doi: 10.1007/s10067-014-2823-8. Epub 2014 Nov 20.

PMID:
25409858
3.

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.

Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C.

J Rheumatol. 2009 Jun;36(6):1273-82. doi: 10.3899/jrheum.080814. Epub 2009 Mar 13.

PMID:
19286847
4.

Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.

Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.

Postgrad Med. 2014 Mar;126(2):65-75. doi: 10.3810/pgm.2014.03.2741.

PMID:
24685969
5.

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

Jackson RL, Hunt B, MacDonald PA.

BMC Geriatr. 2012 Mar 21;12:11. doi: 10.1186/1471-2318-12-11.

6.

As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.

Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, Aringer M, Wunderlich C.

Rheumatol Int. 2014 Jan;34(1):101-9. doi: 10.1007/s00296-013-2857-2. Epub 2013 Sep 12.

PMID:
24026528
7.

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

Wells AF, MacDonald PA, Chefo S, Jackson RL.

BMC Musculoskelet Disord. 2012 Feb 9;13:15. doi: 10.1186/1471-2474-13-15.

8.

Health literacy in patients dealing with gout: a qualitative study.

van Onna M, Hinsenveld E, de Vries H, Boonen A.

Clin Rheumatol. 2015 Sep;34(9):1599-603. doi: 10.1007/s10067-014-2838-1. Epub 2014 Dec 12.

PMID:
25501463
9.

A cross-sectional internet-based patient survey of the management strategies for gout.

Singh JA, Shah N, Edwards NL.

BMC Complement Altern Med. 2016 Mar 1;16:90. doi: 10.1186/s12906-016-1067-3.

10.

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.

Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ.

BMC Musculoskelet Disord. 2012 Sep 16;13:174. doi: 10.1186/1471-2474-13-174.

11.

Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.

Wortmann RL, Macdonald PA, Hunt B, Jackson RL.

Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008.

PMID:
21353107
12.

Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.

Schumacher HR Jr, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP, Yancopoulos GD, Wang J, Terkeltaub R.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1462-70. doi: 10.1002/acr.21690.

13.

Casebook consults: improving outcomes in gout (multimedia activity).

Doghramji PP, Mandell BF, Pope RS.

Am J Med. 2012 Aug;125(8):S1. doi: 10.1016/j.amjmed.2012.06.002.

PMID:
22840678
14.

Patient and clinical characteristics associated with gout flares in an integrated healthcare system.

Rashid N, Levy GD, Wu YL, Zheng C, Koblick R, Cheetham TC.

Rheumatol Int. 2015 Nov;35(11):1799-807. doi: 10.1007/s00296-015-3284-3. Epub 2015 May 20.

15.

Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.

Feng X, Li Y, Gao W.

Joint Bone Spine. 2015 Dec;82(6):428-31. doi: 10.1016/j.jbspin.2015.02.021. Epub 2015 Oct 9.

PMID:
26456042
16.

Febuxostat for treating chronic gout.

Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008653. doi: 10.1002/14651858.CD008653.pub2. Review.

17.

Gout, urate-lowering therapy, and uric acid levels among adults in the United States.

Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC.

Arthritis Care Res (Hoboken). 2015 Apr;67(4):588-92. doi: 10.1002/acr.22469.

18.

Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study.

Abhishek A, Jenkins W, La-Crette J, Fernandes G, Doherty M.

Rheumatology (Oxford). 2017 Apr 1;56(4):529-533. doi: 10.1093/rheumatology/kew395.

PMID:
28082620
19.

[Gout management: an update].

Ankli B, Krähenbühl S.

Ther Umsch. 2016;73(3):115-24. doi: 10.1024/0040-5930/a000766. Review. German.

PMID:
27008442
20.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.

N Engl J Med. 2005 Dec 8;353(23):2450-61.

Supplemental Content

Support Center